Clinical Trial

Clinical Trial Evaluating Safety and Efficacy of Resomelagon on Dengue Infection (RESOVIR-2)

Study acronym: RESOVIR-2
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to understand if Resomelagon can treat adult patients with Dengue virus infection. The main questions the investigators aim to answer are: Is Resomelagon safe to use in patients with Dengue? Is Resomelagon able to reduce the duration of illness? (defined by clinical and laboratory criteria) Participants will be allocated to Resomelagon or placebo groups in this study and asked to take the medication and submitted to blood tests.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-01.
Trial Details
NCT Number NCT06917001
Lead Sponsor Federal University of Minas Gerais
Collaborators: Instituto Nacional de Ciência e Tecnologia em Dengue (INCT em Dengue)
Conditions Dengue Fever
Enrollment 120 participants
Start Date 2026-02
Primary Completion 2027-06 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2025-08-28